Milestone Pharmaceuticals Inc (MIST) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Milestone Pharmaceuticals Inc stock $0.27, price $0.76, that is 64.4% below the price, quality 22 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range $0.6440 – $9.50 · fair‑value band $0.1785 – $0.3400 · the $0.7630 price screens above the $0.2720 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Milestone Pharmaceuticals in your weekly email
Every Wednesday you see whether Milestone Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada.
Show moreShow less
It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil.
Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
Stock analysis
Milestone Pharmaceuticals Inc (MIST) currently trades at $0.7630, while our model-based Fair Value estimate is $0.2720, 64% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $0.1785 (bear) to $0.3400 (bull), the price of $0.7630 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 22/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Milestone Pharmaceuticals Inc reported revenue of $1.5M in FY2025 versus $15.0M in FY2021, a compound −43.3%/yr. Reported net income was −$63.1M in FY2025.
Key figures
Market cap $106M Micro · P/S ratio 40.5 · EPS (TTM) $−0.6800 · Return on equity −35,523% · Return on assets (EBIT) −61.6% (5-year average) · Operating margin −4,585% · Revenue (TTM) $2.3M · Free cash flow −$49.3M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).
What moves the price
The share trades about 74% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −64%, MIST screens richer than that median.
Fair Value models
Bear$0.1785Fair Value $0.2720Bull$0.3400
Price $0.7630 · Downside -64.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham)$0.2100$0.3200$0.400054
All 1 models by family
Asset-Based
NCAV (Graham)$0.2100$0.3200$0.400054
The fair value above starts from this blend and is adjusted for dilution from new shares.
In the last 6 months, no officer or director bought or sold shares on the open market.
SaleJoseph OlivetoPresident and CEO, Director3× since Dec 15, 2025: 247,577 shares, avg. $2.24$555,680Apr 16, 2026
SaleLorenz MullerChief Commercial Officer64,746 shares at $2.25$145,851Jan 26, 2026
SaleAmit HasijaCFO & EVP of Corp. Development70,252 shares at $2.25$158,209Jan 26, 2026
SaleDavid BharuchaChief Medical Officer70,252 shares at $2.25$158,209Jan 26, 2026
SaleJeffrey Edward NelsonChief Operating Officer70,252 shares at $2.25$158,209Jan 26, 2026
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−32.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−36.5%
Start year 2020 (pandemic)
’20
’21
’22
’23
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−338.1% (2020) → −4,041.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Milestone Pharmaceuticals Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 0/6 measures
Overall it trails its industry peers.
Valuation
Quality Score22 · Bottom 25%
Fair Value upside−64.4% · Below median
Profitability
Return on assets−55.5% · Bottom 25%
Balance sheet
Debt / equity1.37× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B2.53× · Pricier than median
P/S (12 months)45.17× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)32· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Milestone Pharmaceuticals Inc (MIST) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of $0.2720 versus a price of $0.7630, about 64% lower (overvalued).
What is the fair value of MIST?
Our model-based fair value for Milestone Pharmaceuticals Inc is $0.2720 (as of Nov 9, 2026), built from audited fundamentals. The current price: $0.7630.
What is the quality score of MIST?
Milestone Pharmaceuticals Inc has a Quality Score of 22/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Milestone Pharmaceuticals Inc (MIST)?
Our model-based price target is the fair value of $0.2720 (as of Nov 9, 2026) from 1 valuation models. Cautious scenario $0.1785, optimistic scenario $0.3400. It is a calculation from audited fundamentals, not an analyst target.
What is the Milestone Pharmaceuticals Inc stock forecast for 2026?
Our models put fair value at $0.2720, about 64% lower versus a price of $0.7630 (overvalued). Cautious scenario $0.1785, optimistic scenario $0.3400. The calculation is refreshed regularly with new filings.
What is the revenue of Milestone Pharmaceuticals Inc (MIST)?
Milestone Pharmaceuticals Inc reported trailing-twelve-month revenue of about $2.3M (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of Milestone Pharmaceuticals Inc (MIST)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Milestone Pharmaceuticals Inc it is $0.2720 per share (as of Nov 9, 2026), against a price of $0.7630. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Milestone Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Nov 9, 2026, MIST trades above its calculated fair value: price $0.7630, fair value $0.2720, a gap of about −64% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MIST?
No. The price is what the market pays today ($0.7630); the fair value is what the company's own numbers justify ($0.2720). For Milestone Pharmaceuticals Inc the two are $0.4910 per share apart. That gap is exactly why we show both numbers side by side.
How much is Milestone Pharmaceuticals Inc worth?
The market values Milestone Pharmaceuticals Inc at about $106M (market capitalisation, as of Nov 9, 2026). Per share that is $0.7630; our models calculate a fair value of $0.2720 per share.
What do the bullish and bearish scenarios say about MIST?
Our models span a range for Milestone Pharmaceuticals Inc: cautious scenario $0.1785, base $0.2720, optimistic $0.3400 per share (as of Nov 9, 2026, price $0.7630). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Milestone Pharmaceuticals Inc (MIST)?
Balance-sheet figures for Milestone Pharmaceuticals Inc (as of Nov 9, 2026): debt of 1.37 per unit of equity. They feed the Quality Score of 22/100, which measures business quality independently of the share price.
How far is MIST from its 52-week high?
Milestone Pharmaceuticals Inc trades at $0.7630, about 74% below its 52-week high of $2.95 and 18% above the low of $0.6440 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.2720 is for.
Which stocks are comparable to Milestone Pharmaceuticals Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Milestone Pharmaceuticals Inc stock attractive at the current price?
The data as of Nov 9, 2026: price $0.7630, calculated fair value $0.2720 (−64%), Quality Score 22/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MIST calculated?
We run Milestone Pharmaceuticals Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $0.2720 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Milestone Pharmaceuticals Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Milestone Pharmaceuticals Inc (MIST)?
The closing price on Nov 6, 2026 was $0.7630. Our model-based fair value is $0.2720, about 64% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Milestone Pharmaceuticals Inc right now?
The price sits above even our optimistic bull case ($0.3400). The favourable scenario is already priced in. Weak quality (22/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.1785 to $0.3400) leaves room in how you read the outcome.
Key figures of Milestone Pharmaceuticals Inc
How large is the market capitalisation of Milestone Pharmaceuticals Inc (MIST)?
The market capitalisation of Milestone Pharmaceuticals Inc is $106M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Milestone Pharmaceuticals Inc (MIST)?
The price-to-sales ratio of Milestone Pharmaceuticals Inc is 40.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Milestone Pharmaceuticals Inc (MIST)?
Earnings per share at Milestone Pharmaceuticals Inc are $−0.6800. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Milestone Pharmaceuticals Inc (MIST)?
The return on equity (ROE) of Milestone Pharmaceuticals Inc is −35,523% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Milestone Pharmaceuticals Inc (MIST)?
On an EBIT basis the return on assets of Milestone Pharmaceuticals Inc is −61.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Milestone Pharmaceuticals Inc (MIST)?
The operating margin of Milestone Pharmaceuticals Inc is −4,585% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Milestone Pharmaceuticals Inc (MIST) generate?
The free cash flow of Milestone Pharmaceuticals Inc is −$49.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Milestone Pharmaceuticals Inc (MIST) hold?
Milestone Pharmaceuticals Inc holds more cash than debt, $14.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Milestone Pharmaceuticals Inc in the live analysis
One click puts Milestone Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 9, 2026
